EPIMMUN® is the process for laser-assisted epidermal immunization by using the P.L.E.A.S.E.® device to deliver the immunogen. The P.L.E.A.S.E.® technology allows to adjust the pore density and depth settings as required to control the dosage and enable targeting of individual skin layers. The microporation process creates an inflammatory stimulus and may thereby boost the immune response.
In a study on BALB/c mice with commercially available conjugate vaccines against Neisseria meningitides (Menveo, GSK) and Haemophilus influenzae Type B (ActHIB_, Sanofi Pasteur). induced high antibody titers after TCI (= with PLEASE), which were comparable to i.m. injection.
A study for epicutaneous immunotherapy to IgE-mediated allergy on BALB/c mice shows effectiveness of EPIMMUN® and to reduce the number of immunotherapy from eight times to 3 times and a duration from three weeks to two weeks, yet with significantly better outcome. The EPIMMUN® enhances Treg cells against administered allergens and suppresses IgE response, whereas provoking little local reaction at the site of patch application and greatly minimizing the risk of anaphylaxis when compared to SCIT. The EPIMMUN® shows great promise to treat IgE-mediated type-1 allergy.
In a study on C57BL/6 mice6, the immunogenicity of a peptide cancer vaccine for liver cancer delivered in the epidermis via the P.L.E.A.S.E.® Professional laser was evaluated in a side-by-side comparison with standard subcutaneous injections of vaccine with or without metronomic chemotherapy. Vaccination with laser assisted immunogen delivery was shown to elicit a significantly higher specific T cell response, as measured by CD4+ as well as CD8+ IFN-γ intracellular staining (see data on the right).